The allosteric modulation of Complement C5 by knob domain peptides

  1. Alex Macpherson  Is a corresponding author
  2. Maisem Laabei
  3. Zainab Ahdash
  4. Melissa A Graewert
  5. James R Birtley
  6. Monika-Sarah ED Schulze
  7. Susan Crennell
  8. Sarah A Robinson
  9. Ben Holmes
  10. Vladas Oleinikovas
  11. Per H Nilsson
  12. James Snowden
  13. Victoria Ellis
  14. Tom Eirik Mollnes
  15. Charlotte M Deane
  16. Dmitri Svergun
  17. Alastair DG Lawson
  18. Jean MH van den Elsen  Is a corresponding author
  1. University of Bath, United Kingdom
  2. UCB-Celltech, United Kingdom
  3. EMBL Hamburg, Germany
  4. University of Oxford, United Kingdom
  5. Oslo University hospital, Sweden
  6. University of Oslo, Norway
  7. EMBL/DESY, Germany

Abstract

Bovines have evolved a subset of antibodies with ultra-long CDRH3 regions that harbour cysteine-rich knob domains. To produce high affinity peptides, we previously isolated autonomous 3-6 kDa knob domains from bovine antibodies. Here, we show that binding of four knob domain peptides elicits a range of effects on the clinically validated drug target complement C5. Allosteric mechanisms predominated, with one peptide selectively inhibiting C5 cleavage by the alternative pathway C5 convertase, revealing a targetable mechanistic difference between the classical and alternative pathway C5 convertases. Taking a hybrid biophysical approach, we present C5-knob domain co-crystal structures and, by solution methods, observed allosteric effects propagating >50 Å from the binding sites. This study expands the therapeutic scope of C5, presents new inhibitors and introduces knob domains as new, low molecular weight antibody fragments, with therapeutic potential.

Data availability

Structural datasets presented in this study have been made publicly available in the Protein Data Bank (PDB) and Small Angle Scattering Biological Data Bank (SASBDB)

The following data sets were generated

Article and author information

Author details

  1. Alex Macpherson

    Biology & Biochemistry, University of Bath, Bath, United Kingdom
    For correspondence
    Alex.MacPherson@ucb.com
    Competing interests
    Alex Macpherson, employee of UCB and may hold shares and/or stock options.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-4508-5322
  2. Maisem Laabei

    Biology and Biochemistry, University of Bath, Bath, United Kingdom
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-8425-3704
  3. Zainab Ahdash

    Immunology, UCB-Celltech, Slough, United Kingdom
    Competing interests
    Zainab Ahdash, employee of UCB and may hold shares and/or stock options.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-4495-8689
  4. Melissa A Graewert

    Biological Small Angle Scattering, EMBL Hamburg, Hamburg, Germany
    Competing interests
    No competing interests declared.
  5. James R Birtley

    Immunology, UCB-Celltech, Slough, United Kingdom
    Competing interests
    James R Birtley, employee of UCB and may hold shares and/or stock options.
  6. Monika-Sarah ED Schulze

    Immunology, UCB-Celltech, Slough, United Kingdom
    Competing interests
    Monika-Sarah ED Schulze, employee of UCB and may hold shares and/or stock options.
  7. Susan Crennell

    Biology & Biochemistry, University of Bath, Bath, United Kingdom
    Competing interests
    No competing interests declared.
  8. Sarah A Robinson

    Statistics, University of Oxford, Oxford, United Kingdom
    Competing interests
    No competing interests declared.
  9. Ben Holmes

    Immunology, UCB-Celltech, Slough, United Kingdom
    Competing interests
    Ben Holmes, employee of UCB and may hold shares and/or stock options.
  10. Vladas Oleinikovas

    Immunology, UCB-Celltech, Slough, United Kingdom
    Competing interests
    Vladas Oleinikovas, employee of UCB and may hold shares and/or stock options.
  11. Per H Nilsson

    Immunology, Oslo University hospital, Oslo, Sweden
    Competing interests
    No competing interests declared.
  12. James Snowden

    Immunology, UCB-Celltech, Slough, United Kingdom
    Competing interests
    James Snowden, employee of UCB and may hold shares and/or stock options.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-4855-7329
  13. Victoria Ellis

    Immunology, UCB-Celltech, Slough, United Kingdom
    Competing interests
    Victoria Ellis, employee of UCB and may hold shares and/or stock options.
  14. Tom Eirik Mollnes

    Department of Immunology, University of Oslo, Oslo, Norway
    Competing interests
    Tom Eirik Mollnes, T.E.M is a Board member of Ra Pharmaceuticals, Inc.
  15. Charlotte M Deane

    Department of Statistics, University of Oxford, Oxford, United Kingdom
    Competing interests
    Charlotte M Deane, Reviewing editor, eLife.
  16. Dmitri Svergun

    Biological Small Angle Scattering, EMBL/DESY, Hamburg, Germany
    Competing interests
    No competing interests declared.
  17. Alastair DG Lawson

    Immunology, UCB-Celltech, Slough, United Kingdom
    Competing interests
    Alastair DG Lawson, employee of UCB and may hold shares and/or stock options.
  18. Jean MH van den Elsen

    Biology & Biochemistry, University of Bath, Bath, United Kingdom
    For correspondence
    bssjmhve@bath.ac.uk
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-0367-1956

Funding

No specific external funding was received for this work.

Copyright

© 2021, Macpherson et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 2,852
    views
  • 439
    downloads
  • 26
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Alex Macpherson
  2. Maisem Laabei
  3. Zainab Ahdash
  4. Melissa A Graewert
  5. James R Birtley
  6. Monika-Sarah ED Schulze
  7. Susan Crennell
  8. Sarah A Robinson
  9. Ben Holmes
  10. Vladas Oleinikovas
  11. Per H Nilsson
  12. James Snowden
  13. Victoria Ellis
  14. Tom Eirik Mollnes
  15. Charlotte M Deane
  16. Dmitri Svergun
  17. Alastair DG Lawson
  18. Jean MH van den Elsen
(2021)
The allosteric modulation of Complement C5 by knob domain peptides
eLife 10:e63586.
https://doi.org/10.7554/eLife.63586

Share this article

https://doi.org/10.7554/eLife.63586

Further reading

    1. Immunology and Inflammation
    2. Microbiology and Infectious Disease
    Axelle Amen, Randy Yoo ... Matthijs M Jore
    Research Article

    Circulating sexual stages of Plasmodium falciparum (Pf) can be transmitted from humans to mosquitoes, thereby furthering the spread of malaria in the population. It is well established that antibodies can efficiently block parasite transmission. In search for naturally acquired antibodies targets on sexual stages, we established an efficient method for target-agnostic single B cell activation followed by high-throughput selection of human monoclonal antibodies (mAbs) reactive to sexual stages of Pf in the form of gametes and gametocyte extracts. We isolated mAbs reactive against a range of Pf proteins including well-established targets Pfs48/45 and Pfs230. One mAb, B1E11K, was cross-reactive to various proteins containing glutamate-rich repetitive elements expressed at different stages of the parasite life cycle. A crystal structure of two B1E11K Fab domains in complex with its main antigen, RESA, expressed on asexual blood stages, showed binding of B1E11K to a repeating epitope motif in a head-to-head conformation engaging in affinity-matured homotypic interactions. Thus, this mode of recognition of Pf proteins, previously described only for Pf circumsporozoite protein (PfCSP), extends to other repeats expressed across various stages. The findings augment our understanding of immune-pathogen interactions to repeating elements of the Plasmodium parasite proteome and underscore the potential of the novel mAb identification method used to provide new insights into the natural humoral immune response against Pf.

    1. Immunology and Inflammation
    Yalan Jiang, Pingping He ... Xiaoou Shan
    Research Article

    Type 1 diabetes mellitus (T1DM), known as insulin-dependent diabetes mellitus, is characterized by persistent hyperglycemia resulting from damage to the pancreatic β cells and an absolute deficiency of insulin, leading to multi-organ involvement and a poor prognosis. The progression of T1DM is significantly influenced by oxidative stress and apoptosis. The natural compound eugenol (EUG) possesses anti-inflammatory, anti-oxidant, and anti-apoptotic properties. However, the potential effects of EUG on T1DM had not been investigated. In this study, we established the streptozotocin (STZ)-induced T1DM mouse model in vivo and STZ-induced pancreatic β cell MIN6 cell model in vitro to investigate the protective effects of EUG on T1DM, and tried to elucidate its potential mechanism. Our findings demonstrated that the intervention of EUG could effectively induce the activation of nuclear factor E2-related factor 2 (NRF2), leading to an up-regulation in the expressions of downstream proteins NQO1 and HMOX1, which are regulated by NRF2. Moreover, this intervention exhibited a significant amelioration in pancreatic β cell damage associated with T1DM, accompanied by an elevation in insulin secretion and a reduction in the expression levels of apoptosis and oxidative stress-related markers. Furthermore, ML385, an NRF2 inhibitor, reversed these effects of EUG. The present study suggested that EUG exerted protective effects on pancreatic β cells in T1DM by attenuating apoptosis and oxidative stress through the activation of the NRF2 signaling pathway. Consequently, EUG holds great promise as a potential therapeutic candidate for T1DM.